BioLineRx Ltd. (BLRX) Latest Filing Signal

Latest Filing: 20-F  |  Filed Mar 23, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for BioLineRx Ltd.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 20-F, BioLineRx Ltd.'s filing signal continuing negative.
earningsVibe SuperAnalyst™ Verdict: CONTINUING NEGATIVE

Signal Performance — Stock Price Since Filing

30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Negative
GEMINI
Turned Positive
CLAUDE
Turned Positive
CHATGPT
Continuing Negative

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does BioLineRx Ltd. actually do?
Answer:
BioLineRx Ltd. is an Israeli biopharmaceutical company focused on developing therapies for oncology and rare diseases. Its lead product, APHEXDA(R) (motixafortide), is approved in the U.S. for stem cell mobilization in multiple myeloma patients and is being commercialized globally through licensing agreements with Ayrmid Pharma Ltd. and Auspex Bioscience (Gloria). The company is also advancing motixafortide for pancreatic cancer and other solid tumors. BioLineRx has a collaboration with Hemispherian AS for GLIX1, a novel small molecule targeting DNA damage response in glioblastoma and other cancers, with an IND application cleared by the FDA in August 2025. The company has refocused its operations on development activities in Israel following the out-licensing of its U.S. commercialization activities.
Question:
What are BioLineRx Ltd.'s revenue drivers?
Answer:
Revenue is primarily driven by upfront payments, milestone payments, and tiered royalties from out-licensing agreements for its lead product, motixafortide, with Ayrmid Pharma Ltd. and Auspex Bioscience (Gloria).

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required